01—Abstract
Summary
Summary of the 10-K filed November 25, 2008. Cited figures are marked; the original filing is the authoritative source.
AmerisourceBergen Corporation (now Cencora, Inc.) reported its 2008 fiscal year-end results, highlighting steady revenue growth driven by its Pharmaceutical Distribution segment.
The company benefited from an aging population and increased use of pharmaceuticals, including generics. Strategic initiatives included optimizing its distribution network and growing its specialty pharmaceutical business through acquisitions like Bellco Health.
The company also divested its workers' compensation business, PMSI, recognizing a significant charge related to this divestiture. Despite facing intense competition and regulatory scrutiny, AmerisourceBergen demonstrated resilience, with management focusing on operational efficiency and strategic growth to navigate the evolving healthcare landscape.
02—Key points
Key Highlights
- Total revenue reached $70.2 billion, a 7% increase year-over-year, primarily driven by the Pharmaceutical Distribution segment.
- Operating income grew 5% to $827.9 million, reflecting improved efficiency in the core distribution business.
- The company completed the acquisition of Bellco Health, bolstering its presence in the New York market and expanding its specialty pharmaceuticals business.
- AmerisourceBergen divested its PMSI workers' compensation business, recognizing a significant non-cash charge of $225.8 million related to the sale.
- The company continued its share repurchase program, buying back $679.7 million of its common stock during fiscal year 2008.
- Significant investments were made in IT infrastructure and business transformation projects, including a new ERP platform, aimed at future cost reductions and operational enhancements.
- The company faced and disclosed various risk factors, including intense competition, potential customer losses, increasing government regulation, and economic uncertainties.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2008, Cencora, Inc. kept $0.00.
- Revenue$70.19B100.0%
- Cost of revenue−$68.14B97.1%
- Gross profit$2.05B2.9%
- Operating costs−$1.22B1.7%
- Operating income$827.9M1.2%
- Interest, other & tax−$577.3M0.8%
- Net income$250.6M0.4%
Where FY2008 revenue went
$70.19B- Cost of revenue: $68.14B, 97% of revenue
- Net income: $250.6M, 0.4% of revenue
- SG&A: $1.12B, 1.6% of revenue
- Interest, other & tax: $577.3M, 0.8% of revenue
Kept 0.4% as net incomeNet income $250.6M · 0.4%
Full revenue history →04—Financials
Financial Highlights
Figures from 10-KFY2008filed November 25, 2008Financial Statements
FY2008 against FY2007
| Line item | FY2008FY2007 | Change |
|---|---|---|
| Revenue | $70.19B$65.67B | +6.9% |
| Cost of Revenue | $68.14B$63.45B | +7.4% |
| Gross Profit | $2.05B$2.22B | −7.8% |
| SG&A Expenses | $1.12B$1.34B | −16.5% |
| Operating Income | $827.86M$788.74M | +5.0% |
| Net Income | $250.56M$469.17M | −46.6% |
| EPS (Basic) | $0.78$1.27 | −38.6% |
| EPS (Diluted) | $0.77$1.25 | −38.4% |
| Shares Outstanding (Basic) | 321.28M370.36M | −13.3% |
| Shares Outstanding (Diluted) | 324.92M375.77M | −13.5% |
05—Questions
Frequently Asked Questions
What was AmerisourceBergen's primary revenue driver in fiscal year 2008?
The primary revenue driver for AmerisourceBergen in fiscal year 2008 was its Pharmaceutical Distribution segment, which contributed significantly to the company's total revenue of $70.2 billion.
What major strategic actions did AmerisourceBergen take during fiscal year 2008?
Key strategic actions included acquiring Bellco Health to expand its market presence and specialty business, divesting its PMSI workers' compensation business, and continuing its share repurchase program. The company also focused on internal initiatives like optimizing its distribution network and investing in business transformation projects.
What were the main challenges or risks highlighted in the filing?
The company identified several key risks, including intense competition from major distributors like Cardinal Health and McKesson, the potential loss of major customers (Medco Health Solutions represented 17% of revenue), increasing government regulation and potential changes in reimbursement policies, and broader economic uncertainties affecting healthcare spending.
How did the company's acquisition strategy impact its financials?
The acquisition of Bellco Health for $162.2 million contributed $2.1 billion in revenues in fiscal 2008 and expanded the company's presence in the New York market and its specialty pharmaceuticals business. Acquisitions in fiscal 2007, such as IgG, Access M.D., and Xcenda, also aimed to bolster specialty services and market reach.
06—Continue